We
~~Patent~~ Claims:

1. Compounds of the formula



(I),

in which

A represents the group



(II)

wherein

m and n independently of one another denote 1 or 2,

Q represents one of the double-bonding groups

$-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-$, $-CH=CH-$,



and

Q' represents the group =NR or the group =NRR', wherein R denotes H or an optionally halogen-substituted or hydroxy-substituted C_1-C_4-alkyl radical, R' denotes a C_1-C_4-alkyl radical and R and R' together may also form a C_4-C_6-alkylene radical, and wherein, in the case of quaternary compounds, one equivalent of an anion (X^-) opposes the positive charge of the N atom,

R_1 represents a thienyl, phenyl, furyl, cyclopentyl or cyclohexyl radical, wherein these radicals may also be methyl-substituted, thienyl and phenyl may also be fluoro-substituted or chloro- substituted,

R_2 represents hydrogen, OH, C_1-C_4-alkoxy or C_1-C_4-alkyl,

R_3 represents H, F, Cl or CH_3 and, if =NR denotes a secondary or tertiary amino group, also the acid addition salts,

2. Compounds according to claim 1, wherein R_1 represents 2-thienyl.

3. Compounds according to claim 1 or 2, wherein R_2 represents OH.

4. Compounds according to claim 1, 2 or 3, wherein A represents





wherein R and X⁻ have the above meaning and R' has the above meaning except for hydrogen.

5. Compounds according to claims 1 to 4, in which R_1 denotes 2-thienyl and A represents the radical



or



in the 3α-form, wherein X^- is one equivalent of an anion, preferably Br^- or $CH_3SO_3^-$.

6. Medicaments characterised in that they contain a compound according to claims 1, 2, 3, 5 or 11 in addition to conventional auxiliaries and/or excipients.

7. Use of compounds according to claims 1 to 5 in the treatment of diseases.

8. Use of compounds according to claims 1 to 5 in the preparation of anti-cholinergic medicaments.

9. Use of compounds according to claims 1 to 5 in the preparation of medicaments for the treatment of respiratory tract diseases and sinus bradycardia.

10. Process for the preparation of compounds according to claims 1 to 5, characterised in that an ester of the formula



(IV),

wherein R" represents a C_1-C_4-alkyl radical and R_1, R_2 and R_a have the above meaning, is transesterified using an

amino alcohol of the formula



(V)

wherein m, n and Q have the above meaning and Q" represents =NR or =NH, in an inert organic solvent or in a melt, in the presence of a transesterification catalyst, and the compound obtained is optionally quaternised

a) if Q" denotes =NR (R ≠ H), using a reactive monofunctionalised derivative Z-(C_1-C_4-alkyl) of an alkane (Z = leaving group)

or is optionally substituted and quaternised

b) if Q" denotes =NH, using a terminally disubstituted alkane Z-(C_4-C_6-alkylene)-Z without isolation of intermediates.

11. Compounds of the formula



in the 3α-form and their acid addition salts and their methobromides or methomethanesulphonates.

12. Use of compounds of the formula I, wherein Q' denotes =NR, and their salts as intermediate products for the preparation of the corresponding quaternary compounds of the formula I.